| Literature DB >> 25025076 |
Heshu Sulaiman Rahman1, Abdullah Rasedee2, Swee Keong Yeap3, Hemn Hassan Othman4, Max Stanley Chartrand5, Farideh Namvar6, Ahmad Bustamam Abdul3, Chee Wun How3.
Abstract
Zerumbone (ZER) is a naturally occurring dietary compound, present in many natural foods consumed today. The compound derived from several plant species of the Zingiberaceae family that has been found to possess multiple biomedical properties, such as antiproliferative, antioxidant, anti-inflammatory, and anticancer activities. However, evidence of efficacy is sparse, pointing to the need for a more systematic review for assessing scientific evidence to support therapeutic claims made for ZER and to identify future research needs. This review provides an updated overview of in vitro and in vivo investigations of ZER, its cancer chemopreventive properties, and mechanisms of action. Therapeutic effects of ZER were found to be scientifically plausible and could be explained partially by in vivo and in vitro pharmacological activities. Much of the research outlined in this paper will serve as a foundation to explain ZER anticancer bioactivity, which will open the door for the development of strategies in the treatment of malignancies using ZER.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25025076 PMCID: PMC4082908 DOI: 10.1155/2014/920742
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Zingiber zerumbet tree (a) and inflorescences (b).
Figure 2Zingiber zerumbet rhizome (a) and essential oil (b).
Figure 3Zerumbone pure crystals (a) and chemical structure (b).
Characteristic features of zerumbone.
| Characters | Description |
|---|---|
| Natural occurrence |
|
| Chemical class | Sesquiterpene |
| Chemical formula | (2E, 6E, 10E)-2,6,9,9-tetramethylcycloundeca-2,6,10-trien-1-one |
| Molecular formula | C15H22O |
| Chemical structure | Three-double bond (two conjugated and one isolated), |
| Molecular weight | 218.3 dalton |
| Flashing point | 272°F |
| Boiling point | 321-322°C at 760 mmHg |
| Melting point | 65.3°C |
| Vapor pressure | 0.000295 mm/Hg at 25°C |
| Purity | 92–100% |
| Appearance | Solid white crystals or powder |
| Short term storage | +4°C |
| Stability | Stable for at least 2 years when stored at −20°C |
| Solubility | Completely soluble in ethanol, DMSO, while solubility in water is approximately 1.296 mg/L at 25°C |
| Extraction | Mainly isolated from fresh rhizomes by hydrodistillation (steam distillation) and recrystallization methods |
| Usage | For researches and medical purposes, not for flavor or fragrance |
In Vitro biological effects of zerumbone.
| Organ | Cell line | Biological effect of ZER |
|---|---|---|
| Blood | Human acute lymphocytic leukemia (CEM-ss) [ | Induces apoptosis and DNA internucleosomal degradation activate caspase-3 |
| Human acute lymphoblastic leukemia (Jurkat) [ | Induces G2/M cell cycle arrest | |
| Human chronic myeloid leukemia (KBM-5) [ | Induces cytotoxicity | |
| Human acute promyelocytic leukemia (HL-60) [ | Suppresses TPA-induced superoxide anion generation from NADPH oxidase | |
| Human acute promyelocytic leukemia (NB4) [ | Induces G2/M cell cycle arrest associated with decline of cyclin B1 protein and phosphorylation of ATM/Chk1, induced apoptosis via expression of Fas (CD95)/Fas ligand (CD95L), with the activation of caspase-8 | |
| Human acute myelocytic leukemia (U937) [ | Antagonizes action of DDT and TCDD by upregulating the expressions of COX-2 and VEGF mRNA | |
| Human acute lymphoblastic leukemia (MOLT4), human acute lymphocytic leukemia (OKM-2T), and human chronic myelocytic leukemia (K562 and KT-1) [ | No cytotoxicity at concentration of 10 | |
| Human peripheral blood multiple myeloma (U266) [ | Suppresses CXCR4 expression | |
| Murine lymphoid neoplastic (P-388D1) [ | Causes DNA fragmentation and growth inhibition | |
| Murine acute myelocytic leukemia (WEHI-3B) [ | Induces G2/M cell cycle arrest and apoptosis | |
| Normal human umbilical vein endothelial cell (HUVEC) [ | Does not inhibit proliferation at concentration of 10 | |
| Normal human primary mononuclear cells (PBMCs) [ | No cytotoxicity (1–100 µg/mL) | |
| Mice thymocytes and splenocytes human PBMC [ | Stimulates time- and dose-dependent proliferation of mice cells and human PBMC | |
| Human peripheral blood lymphocytes (PBL) Al [ | Cytotoxic but not clastogenic at 40 and 80 | |
| Lymphoblastoid (Raji) cells | Suppresses tumor promoter 12- | |
| Human monocyte-like cells (THP-1) [ | Suppresses TPA-induced LOX-1 mRNA expression | |
| Normal murine macrophages 9RAW264.7) [ | Markedly diminishes inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 expression | |
| Immortalized mouse embryonic fibroblasts (SV40) [ | Not cytotoxic | |
| Human whole blood [ | Inhibits platelet aggregation induced by arachidonic acid (AA), collagen, and ADP | |
| Skin | Human melanoma (WM1552C) [ | Induces apoptosis and autophagy |
| Murine melanoma (B16-F0) [ | Induces apoptosis and autophagy | |
| Normal human dermal fibroblast (2F0-C25) [ | Not cytotoxic at a concentration of 13 | |
| Murine epidermal cells (JB6 Cl41) [ | Induces heme oxygenase-1 expression through activation of Nrf2 | |
| Liver | Human liver adenocarcinoma (HepG2) [ | Induces apoptosis via up- and downregulation of Bax/Bcl-2 proteins independent of functional p53 activity |
| Human hepatoma (HTC) [ | Cytotoxic | |
| Murine hepatoma cells (Hepa1c1c7) [ | Marked upregulation of multiple HSPs, such as HSP40 and HSP70HSPs | |
| Normal human liver cells (Chang) [ | Inhibits cell growth with an IC50 value of 10.96 ± 0.059 | |
| Normal rat liver epithelial cells (RL34) [ | Activates phase II drug metabolizing enzymes, such as GST (glutathione S-transferase), epoxide hydrolase, and hemeoxygenase via the transcription factor Nrf2 dependent pathway | |
| Normal human liver cells (WRL-68) [ | Not cytotoxic | |
| Cervical | Human cervical cancer (HeLa) [ | Causes growth inhibition and induces apoptosis |
| Colon | Human colonic adenocarcinoma (Caco-2, Colo320DM, and HT-29) [ | Markedly induces expressions of interleukin (IL)-1 |
| Human colonic adenocarcinoma (LS174T, LS180, COLO205, COLO320DM) [ | Inhibits cell proliferation in dose-dependent manner | |
| Normal human colon fibroblast (CCD-18Co) [ | Not cytotoxic at a concentration of 13 | |
| Colorectal | Human colorectal carcinoma (HCT116) [ | Enhances TRAIL-induced apoptosis |
| Human colon carcinoma (HCT-116) [ | Induces apoptosis | |
| Bile duct | Poorly differentiated adenocarcinoma (KKU-100), squamous cell carcinoma (KKU-M139), moderately differentiated adenocarcinoma (KKU-M156), adenosquamous carcinoma (KKUM213), and moderately differentiated adenocarcinoma (KKU-M214) [ | ZER derivatives (5, 10, 14, and 20) showed antiproliferative activity |
| Breast | Human breast adenocarcinoma cell lines (MCF-7 and MDA-MB 231) [ | G2/M phase cell cycle arrest |
| Not cytotoxic | ||
| Ovarian | Human ovarian cancer (Caov-3) [ | Causes growth inhibition and induces apoptosis |
| Normal Chinese hamster ovarian cells (AS52) [ | Suppresses tumor promoter 12-O-tetradecanoylphorbol-13-acetate- (TPA-) induced superoxide anion (O2 −) generation from xanthine oxidase (XO) | |
| Normal Chinese hamster ovary cells (CHO) [ | High concentrations produce genotoxic and cytotoxic effects (40–80 µM) | |
| Pancreatic | Human pancreatic carcinoma (PaCa) [ | Novel inhibitor of Jak2/Stat3, which inhibits promigratory gene expression, growth, and migration of pancreatic cancer cells |
| Human pancreatic cancer (PANC-28, MIA PaCa-2, and AsPC-1) [ | Inhibits CXCL12-induced invasion of pancreatic tumor cells | |
| Human pancreatic carcinoma (PANC-1 and SW1990) [ | Time-dependent inhibition of cell viability induces apoptosis | |
| Human pancreatic carcinoma (PaCa) [ | Inhibits PaCa-associated angiogenesis through the inhibition of NF- | |
| Lung | Human nonsmall cell lung carcinoma (H1299 cells) [ | Enhances TNF-induced cytotoxicity and potentiates apoptosis |
| Human small cell lung carcinoma (NCI-H187) [ | Inhibits monomeric form of the HSP 27 protein | |
| Kidney | Human embryonic kidney carcinoma cell line (A293 cells) [ | Inhibits cell growth |
| Bovine normal kidney cell line (MDBK) [ | Inhibits cell growth with an IC50 value of 10.02 ± 0.03 | |
| Human kidney embryonic cells (HEK 293) [ | ZER derivative (parent alcohol 8) could protect irradiation induced cell apoptosis and DNA damage, at least partly, via activation of Keap1/Nrf2/ARE pathway | |
| Normal African green monkey kidney cells (Vero) [ | Nonsignificant cytotoxicity with IC50 of 30 µM. | |
| Brain | Human brain malignant glioma (GBM8401) [ | Induces human glioblastoma multiforme cell apoptosis via inhibition of the IKK |
| Human brain malignant glioma (U87MG) [ | Significantly decreases cell viability at the concentration of 30 and 50 | |
| Prostate | Human adenocarcinoma (DU145) [ | Induces cytotoxicity and significant PARP cleavage |
| Human adenocarcinoma (PC3) [ | Induces nonsignificant expression of DR4 | |
| Stomach | Human gastric adenocarcinoma (AGS) [ | Inhibits tumor angiogenesis via reduction of VEGF production and NF- |
| Oral | Human oral cancer (KB) [ | ZER derivative (parent alcohol 8) induces strong cytotoxicity |
| Headand neck | Human squamous cell carcinomas (SCC4) [ | Suppresses CXCR4 expression and cancer invasion and metastasis |
| Human squamous cell carcinoma (LICR-LONHN5) [ | Inhibits activation of NF- | |
| Pharynx | Human squamous cell carcinoma (FaDu) [ | Inhibits NF- |
| Bone | Mouse macrophage (RAW 264.7) [ | Inhibits RANKL-induced NF- |
In Vivo biological effects of zerumbone.
| Organ | Animal model | ZER route | Biological effect of ZER |
|---|---|---|---|
| Cervix | Female BALB/c mice [ | Intraperitoneal injection | Suppresses cervical intraepithelial neoplasia in female Balb/c mice prenatally exposed to diethylstilbestrol (DES) |
| Colon | Male Sprague Dawley rats [ | Oral dose | Suppresses azoxymethane- (AOM-) induced colon cancer using aberrant crypt foci (ACFs) as a preneoplastic marker |
| Male ICR mice [ | Oral dose | Inhibits multiplicity of colonic adenocarcinomas induced by azoxymethane (AOM) | |
| Female ICR mice [ | Oral dose | Suppresses acute ulcerative colitis (UC) induced by dextran sodium sulfate (DSS) | |
| Male F344 rats [ | Oral dose | Reduces development AOM-induced colonic aberrant crypt foci | |
| Liver | Male Sprague Dawley rats [ | Intraperitoneal injection | Protects rat liver from carcinogenic effects of DEN and AAF |
| Male Sprague Dawley rats [ | Oral dose | Suppresses fatty liver formation induced by overdosage of ethanol | |
| Male golden Syrian hamsters [ | Oral dose | Attenuates nonalcoholic fatty liver disease | |
| Male Sprague Dawley rats [ | Oral dose | Upregulates heat shock protein expressions in the liver | |
| Lung | Female A/J mice [ | Oral dose | Significantly inhibits multiplicity of lung adenomas induced by 4-(Nmethyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) |
| Breast | Female Sprague Dawley rats [ | Intraperitoneal injection | Inhibits tumor growth via Wnt pathway in LA-7 bearing rats |
| Female severe combined immune deficient (SCID) mice [ | Intraperitoneal injection | Retards growth of orthotopic MDA-MB-231 xenografts in association with apoptosis induction and suppression of cell proliferation (Ki-67 expression) | |
| Female BALB/c nu/nu mice [ | Intraperitoneal injection | Decreases osteolytic bone metastasis in MDA-MB-231 bearing athymic nude mice dose dependently | |
| Blood | WEHI-3B bearing male BALB/c mice [ | Oral dose | Induces apoptosis via the mitochondrial intrinsic pathway |
| CDF mice [ | Intraperitoneal injection | Significantly prolongs life of P-388D1-bearing CDF mice | |
| Skin | C57 BL/6 male mice [ | Intraperitoneal injection | Significantly reduces tumor mass and lung metastasis in B16-F0 bearing mice through the activation of Akt and MAPK and inhibition of NF- |
| ICR mice [ | Topical application | Suppresses 7,12-dimethylbenz[ | |
| Female HR-1 hairless mice [ | Topical application | Induces HO-1 expression through activation of Nrf2 | |
| Paw | Mice [ | Intraperitoneal injection | Inhibits carrageenan-induced paw edema dose dependently |
| Eye | ICR mice [ | Oral dose | Protects mouse cornea from ultraviolet B- (UVB-) |
| Pancreas | Male Wistar rats [ | Oral dose | Suppresses cholecystokinin octapeptide- (CCK-8-) induced acute pancreatitis |
| Male SPF Wistar rats [ | Intravenous injection | Attenuates severity of acute necrotizing pancreatitis induced by sodium taurocholate and pancreatitis-induced hepatic injury, via inhibition of NF- | |
| Bone | Male Sprague Dawley rats [ | Oral dose | Reduces inflammatory process in collagen-induced osteoarthritis (OA) |
| Male Sprague Dawley rats [ | Oral dose | Produces chondroprotective effects in MIA-induced knee osteoarthritis | |
| Miscellaneous | Male ICR mice [ | Intraperitoneal injection | Produces pronounced antinociception against chemical models of nociception through L-arginine-nitric oxide-cGMP-PKC-K+ ATP channel pathways, the TRPV1, and kinin B2 receptors |
| Male BALB/c mice [ | Intraperitoneal injection | Produces significant peripheral and central antinociceptive effects when assessed in acetic acid-induced abdominal writhing and hot-plate test models | |
| Female and male BALB/c mice [ | Oral dose | No toxic effects to liver and renal tissues | |
| Female and male ICR mice [ | Intraperitoneal injection | Does not cause mortality or change in the general condition, growth, organ weights, hematology, serum biochemistry, or histopathology after a single dosage of 500 mg/kg or multiple dosage of f 5, 25, and 50 mg/kg for a period of 28 days | |
| Female Sprague Dawley rats [ | Single intraperitoneal injection | Not toxic to liver and renal tissues at dose of 100–200 mg/kg | |
| Male Sprague Dawley rats [ | Intraperitoneal injection | Induces significant increase in the frequency of micronuclei in polychromatic erythrocytes (PCEs) at dose 1000 mg/kg after 24-hour injection | |
| Female Sprague Dawley rats [ | Intraperitoneal injection | Beneficial in cisplatin-induced renal dysfunction, toxicity, and organ damage via preservation of antioxidant glutathione and prevention of lipid peroxidation | |
| Male New Zealand white rabbits [ | Oral dose | Significantly averts and decreases early atheroma plague formation and development via reduction in monocytes and/or macrophages migration, aggregation, and smooth muscle cells proliferation in rabbits fed on cholesterol-rich diet | |
| Male golden Syrian hamsters [ | Oral dose | Improves dyslipidemia by modulating the genes expression involved in the lipolytic and lipogenic pathways of lipids metabolism | |
| Male Wistar rats [ | Oral dose | Ameliorates streptozotocin-induced diabetic nephropathy (DN) by reducing the hyperglycemia-induced inflammatory response |
Figure 4Zerumbone derivatives. (a) (±)-[6E, 10E]-3amino-2,6,9,9-tetramethylcloundeca-6,10-dienone (5), (b) (±)-[6E, 10E]-3-butylamino-2,6,9,9-tetramethylcloundeca-6,10-dienol (10),(c) (±)-[10E]-3-butylamino-6,7-epoxy-2,6,9,9-tetramethylcloundeca-10-enone (14), and (d) (±)-[2E, 6E]-10-cyano-2,6,9,9-tetramethylcloundeca-2,6-dienone (20).
Figure 5Zerumbone imidazole and ring opening derivatives. (a) Parent alcohol 8 (2E,6Z,10E)-13-Hydroxy-2,9,9-trimethylcycloundeca-2,6,10-trienone, (b) NH0891 ([2E,6E,10E/Z0]-11-bromo-4,4,7-trimethyl-2,6,10-dodecatrienoic acid), and (c) 4 (10E/10Z = 3/2).
Figure 6Zerumbone derivatives. (a) Azazerumbone 1, and (b) azazerumbone 2.